Sandra Levy
ARTICLES BY THIS AUTHOR
- 3/27/2023
Camber rolls out generic Thyro-Tabs
Levothyroxine sodium tablets are indicated as replacement therapy in primary, secondary and tertiary congenital or acquired hypothyroidism. - 3/27/2023
DG Media Network unveils ad solutions for Meta platforms
Advertisers can now reach DG’s more than 90 million unique customer profiles across the Meta ecosystem via Facebook and Instagram news feeds, stories and reels. - 3/27/2023
Sandoz receives FDA nod for biosimilar Hyrimoz citrate-free HCF formulation
The formulation is approved to treat seven indications, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis. - 3/27/2023
Walgreens Boots Alliance reports Q2 results
WBA's U.S. healthcare segment's businesses grew sales at a combined rate of 30% in the quarter. - 3/27/2023
Giant donates nearly 3,900 hams, turkeys and chickens to eliminate hunger
From March 31-April 9, customers can donate their free ham certificates in-store at the register or 400 CHOICE points online, for which Giant will donate $10 to a local food bank. - 3/26/2023
Hikma launches generic Vascepa
Icosapent ethyl capsules are indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. - 3/26/2023
Wakefern taps Mike Stigers to serve as president
Mike Stigers will succeed Joe Sheridan, who announced his retirement last year and will remain with the company through the end of the calendar year. - 3/23/2023
CV Sciences releases +PlusCBD Daily Balance THC Free line
+PlusCBD Daily Balance THC-Free products provide the benefits of CBD without the effects of THC, the company said. - 3/23/2023
NCPA 2023 Congressional Pharmacy Fly-In to feature Comer, Bedoya
The fly-in will focus on ways community pharmacies can serve their constituents and what changes to the payment model are needed to best care for them in the future. - 3/23/2023
Coya Therapeutics inks deal with Dr. Reddy’s to license proposed biosimilar Abatacept
The proposed Abatacept biosimilar is a dual biologic intended to suppress neuroinflammation via multiple immunomodulatory pathways, for the treatment of neurodegenerative conditions.
